You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immuno-Oncology Therapeutics

Showing 1 - 25 of 3,881
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in Dallas

Recruiting
  • Cancer
    • Dallas, Texas
      Baylor Scott & White Research Institute
    May 11, 2022

    Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)

    Not yet recruiting
    • Gastroesophageal Adenocarcinoma
    • toripalimab FOLFOX
    • (no location specified)
    Aug 3, 2023

    Kidney Cancer, Clear Cell Renal Cell Carcinoma Metastatic, Synchronous Tumor Trial in Seoul (Cytoreductive

    Recruiting
    • Kidney Cancer
    • +2 more
    • Cytoreductive nephrectomy±metastasectomy
    • Human-derived materials sampling
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Mar 2, 2023

    Biospecimen Procurement for Center for Immuno-Oncology

    Recruiting
    • Multiple Myeloma
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Jul 13, 2022

      NSCLC Trial in Marseille (Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447))

      Recruiting
      • Non-small Cell Lung Cancer
      • Durvalumab (MEDI4736)
      • +5 more
      • Marseille, France
        Assistance Publique Hopitaux de Marseille
      Sep 21, 2022

      NSCLC Patients Trial in Marseille (procedure, diagnostic test, other)

      Recruiting
      • Non-small Cell Lung Cancer Patients
      • BIOPSY
      • +2 more
      • Marseille, France
        Assistance Pubique Hopitaux de Marseille
      Sep 21, 2022

      Solid Carcinoma Trial in Seoul (fecal microbiota transplantation)

      Recruiting
      • Solid Carcinoma
      • fecal microbiota transplantation
      • Seoul, Korea, Republic of
        Asan Medical Center
      Feb 13, 2020

      Solid Tumor Trial in Beijing (GLS-012, GLS-010)

      Recruiting
      • Solid Tumor
      • Beijing, China
        Beijing Cancer Hospital
      Jun 11, 2023

      Malignancy, Immune System Diseases, Autoimmune Diseases Trial in Chapel Hill (Biospecimen Collection, Medical Chart Review,

      Recruiting
      • Malignancy
      • +2 more
      • Biospecimen Collection
      • +2 more
      • Chapel Hill, North Carolina
        Lineberger Comprehensive Cancer Center at University of North Ca
      Feb 11, 2022

      Circulating Tumor DNA Kinetics in Immuno-oncology

      Completed
      • Head and Neck Cancer
      • +4 more
        • Toronto, Ontario, Canada
          Princess Margaret Cancer Centre
        May 16, 2022

        Renal Cell Carcinoma Trial in Amsterdam, London (Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab)

        Recruiting
        • Renal Cell Carcinoma
        • Neoadjuvant nivolumab
        • +2 more
        • Amsterdam, NH, Netherlands
        • +1 more
        May 3, 2022

        Cabozantinib Post First-line Immuno-oncology Checkpoint

        Completed
        • Advanced Renal Cell Carcinoma (aRCC)
          • Glasgow, United Kingdom
          • +8 more
          Jun 30, 2022

          Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma Trial in United States (XL092,

          Recruiting
          • Renal Cell Carcinoma
          • +3 more
          • Tucson, Arizona
          • +3 more
          Mar 30, 2022

          Metastatic Uveal Melanoma in the Liver Trial in United States (SD-101, Nivolumab, Ipilimumab)

          Recruiting
          • Metastatic Uveal Melanoma in the Liver
          • Los Angeles, California
          • +9 more
          Jan 27, 2023

          Oncology Trial in Los Altos

          Recruiting
          • Oncology
            • Los Altos, California
              Cancer Commons
            Jan 31, 2023

            Locally Advanced Pancreatic Adenocarcinoma Trial in Houston (SD-101, pebrolizumab)

            Recruiting
            • Locally Advanced Pancreatic Adenocarcinoma
            • Houston, Texas
              MD Anderson Cancer Center
            Nov 18, 2022

            Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

            Not yet recruiting
            • Inflammatory Arthritis
            • Immune-related Adverse Event
            • (no location specified)
            Sep 13, 2023

            Childhood Cancer, Cancer Trial (MPL-001, MPL-005, MPL-009)

            Not yet recruiting
            • Childhood Cancer
            • Cancer
            • (no location specified)
            Mar 3, 2023

            Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in Houston (SD-101, Pembrolizumab, Nivolumab)

            Recruiting
            • Hepatocellular Carcinoma
            • Intrahepatic Cholangiocarcinoma
            • New York, New York
            • +3 more
            Oct 19, 2022

            Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

            Not yet recruiting
            • Multiple Myeloma
            • Miami, Florida
              University of Miami
            Oct 20, 2023

            Learn About First and Later Lines of Medicines in Treating

            Completed
            • Metastatic Renal Cell Carcinoma
              • New York, New York
                Pfizer Headquarters
              May 12, 2023

              Tumor, Solid Trial in United States (BDB001, Atezolizumab)

              Active, not recruiting
              • Tumor, Solid
              • Los Angeles, California
              • +4 more
              Jul 6, 2022

              Solid Tumor, Adult Trial in United States (IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy)

              Recruiting
              • Solid Tumor, Adult
              • Scottsdale, Arizona
              • +5 more
              Apr 14, 2022

              Prospective Procurement of Tumor Tissue to Identify Novel

              Enrolling by invitation
              • Solid Tumors
              • +7 more
                • Bethesda, Maryland
                  National Institutes of Health Clinical Center
                Feb 2, 2023

                HCC Trial in Hong Kong (Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib)

                Not yet recruiting
                • HCC
                • Zabadinostat (CXD101) and Geptanolimab
                • Lenvatinib and Sorafenib
                • Hong Kong, Hong Kong
                  Department of Clinical Oncology, Prince of Wales Hospital
                May 15, 2023